"Cyclohexanols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.
| Descriptor ID |
D003511
|
| MeSH Number(s) |
D02.033.415.510.500 D02.455.426.392.368.367.318 D10.289.510.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclohexanols".
Below are MeSH descriptors whose meaning is more specific than "Cyclohexanols".
This graph shows the total number of publications written about "Cyclohexanols" by people in this website by year, and whether "Cyclohexanols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 4 | 3 | 7 |
| 2009 | 5 | 0 | 5 |
| 2010 | 5 | 1 | 6 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 4 | 0 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclohexanols" by people in Profiles.
-
Ronca RD, Myers AM, Ganea D, Tuma RF, Walker EA, Ward SJ. A selective cannabinoid CB2 agonist attenuates damage and improves memory retention following stroke in mice. Life Sci. 2015 Oct 01; 138:72-7.
-
Clayton AH, Tourian KA, Focht K, Hwang E, Cheng RF, Thase ME. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015 May; 76(5):562-9.
-
Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr; 31(4):809-20.
-
Findling RL, Groark J, Chiles D, Ramaker S, Yang L, Tourian KA. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014 May; 24(4):201-9.
-
Tourian K, Wang Y, Ii Y. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol. 2013 Jul; 28(4):206-13.
-
Liebowitz MR, Tourian KA, Hwang E, Mele L. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013 Mar 22; 13:94.
-
Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial. J Clin Psychiatry. 2013 Feb; 74(2):158-66.
-
Iwata N, Tourian KA, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 50?mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013 Jan; 19(1):5-14.
-
Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2012 Sep; 17(3):121-30.
-
Adhikary S, Li H, Heller J, Skarica M, Zhang M, Ganea D, Tuma RF. Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. J Neurotrauma. 2011 Dec; 28(12):2417-27.